Valentina Ambrosini, Martyn Caplin, Justo P Castaño, Emanuel Christ, Timm Denecke, Christophe M Deroose, Clarisse Dromain, Massimo Falconi, Simona Grozinsky-Glasberg, Rodney J Hicks, Johannes Hofland, Andreas Kjaer, Ulrich Peter Knigge, Beata Kos-Kudla, Anna Koumarianou, Balkundi Krishna, Angela Lamarca, Marianne Pavel, Nicholas Simon Reed, Aldo Scarpa, Rajaventhan Srirajaskanthan, Anders Sundin, Christos Toumpanakis, Vikas Prasad
Somatostatin receptor (SST) PET/CT is the gold standard for well-differentiated neuroendocrine tumours (NET) imaging. Higher grades of neuroendocrine neoplasms (NEN) show preferential [18F]FDG (FDG) uptake, and even low-grade NET may de-differentiate over time. FDG PET/CT's prognostic role is widely accepted; however, its impact on clinical decision-making remains controversial and its use varies widely. A questionnaire-based survey on FDG PET/CT use and perceived decision-making utility in NEN was submitted to the ENETS Advisory Board Meeting attendees (November 2022, response rate = 70%)...
December 14, 2023: Journal of Neuroendocrinology